|
|
Blood, 1 October 2004, Vol. 104, No. 7, pp. 2081-2083.
Prepublished online as a Blood First Edition Paper on May 4, 2004; DOI 10.1182/blood-2004-02-0715.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Brief report
Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura
Toshihiro Uchida,
Hideo Wada,
Minoru Mizutani,
Miho Iwashita,
Hiroaki Ishihara,
Toshiro Shibano,
Misako Suzuki,
Yumiko Matsubara,
Kenji Soejima,
Masanori Matsumoto,
Yoshihiro Fujimura,
Yasuo Ikeda, and
Mitsuru Murata, for The Research Project on Genetics of Thrombosis
From New Product Research Laboratories II, Daiichi Pharmaceutical, Tokyo, Japan; Department of Laboratory Medicine, Mie University School of Medicine, Tsu, Japan; Department of Internal Medicine, Yamada Red Cross Hospital, Watarai-gun, Japan; Department of Medicine, Keio University, Tokyo, Japan; First Research Department, The Chemo-Sero-Therapeutic Research Institute, Kumamoto, Japan; and Department of Blood Transfusion, Nara Medical University, Kashihara, Japan.
Congenital thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) is associated with an inherited von Willebrand factor-cleaving protease (ADAMTS13 [a disintegrin and metalloprotease with thrombospondin type I domains 13]) deficiency. In this study, we identified novel mutations in the ADAMTS13 gene in a patient with TTP. The patient was a 51-year-old Japanese male who exhibited TTP symptoms at frequent intervals. The ADAMTS13 activity during acute episodes was less than 3% that of normal. The enzyme activities of the patient's father and mother were both 46%, and both parents were asymptomatic. Genetic analysis revealed that the patient was a compound heterozygote for 2 mutations. One mutation was a missense mutation in the metalloprotease domain (A250V, exon 7), and the other was a guanine to adenine substitution at the 5' end of intron 3 (intron 3 G A). In vitro expression studies revealed that the A250V mutation markedly reduced ADAMTS13 activity and the intron 3 GA mutation caused abnormal mRNA synthesis. (Blood. 2004;104: 2081-2083)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Galbusera, M. Noris, and G. Remuzzi
Inherited thrombotic thrombocytopenic purpura
Haematologica,
February 1, 2009;
94(2):
166 - 170.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Garagiola, C. Valsecchi, S. Lavoretano, H. Oren, M. Bohm, and F. Peyvandi
Nonsense-mediated mRNA decay in the ADAMTS13 gene caused by a 29-nucleotide deletion
Haematologica,
November 1, 2008;
93(11):
1678 - 1685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Plaimauer, J. Fuhrmann, G. Mohr, W. Wernhart, K. Bruno, S. Ferrari, C. Konetschny, G. Antoine, M. Rieger, and F. Scheiflinger
Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation
Blood,
January 1, 2006;
107(1):
118 - 125.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Zhou, L. Dong, D. Ginsburg, E. E. Bouhassira, and H.-M. Tsai
Enzymatically Active ADAMTS13 Variants Are Not Inhibited by Anti-ADAMTS13 Autoantibodies: A NOVEL THERAPEUTIC STRATEGY?
J. Biol. Chem.,
December 2, 2005;
280(48):
39934 - 39941.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. De Cristofaro, F. Peyvandi, R. Palla, S. Lavoretano, R. Lombardi, G. Merati, F. Romitelli, E. Di Stasio, and P. M. Mannucci
Role of Chloride Ions in Modulation of the Interaction between von Willebrand Factor and ADAMTS-13
J. Biol. Chem.,
June 17, 2005;
280(24):
23295 - 23302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
